Core Viewpoint - U.S. drugmaker Pfizer announced that its experimental drug for a chronic skin disease successfully met the primary endpoint in a mid-stage clinical trial [1] Group 1 - Pfizer's experimental drug targets a chronic skin disease [1] - The mid-stage study results indicate positive efficacy for the drug [1]